RARE — Ultragenyx Pharmaceutical Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1515673 ·
Last close
$14.50
Market Cap
$1.43B
52W High
$39.89
52W Low
$12.73
ADV30
5,316,360
Next earnings
2026-11-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 214,000,000 | 180,000,000 | -75,000,000 | -92,000,000 | 1,264,000,000 | 125,000,000 | 1,548,000,000 |
| Mar 2026 | 136,000,000 | 106,000,000 | -169,000,000 | -185,000,000 | 1,296,000,000 | 175,000,000 | 1,525,000,000 |
| Dec 2025 | 207,279,000 | 177,934,000 | -113,283,000 | -128,556,000 | 1,532,000,000 | 421,000,000 | 1,605,000,000 |
| Sep 2025 | 159,933,000 | 131,942,000 | -170,890,000 | -180,413,000 | 1,190,445,000 | 202,510,000 | 1,174,286,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-485,000,000
Investing CF
$40,000,000
Financing CF
$477,806,000
CapEx
$-9,000,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-5.84
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-4,809,000,000
Inventory
$59,000,000
Receivables
$200,000,000
ST Investments
$167,000,000
EBIT TTM
$-505,609,000
Pretax Income TTM
$-582,226,000
Interest Exp TTM
$76,617,000
Analysts
19
Yahoo Snapshot (yfinance, live)
Total Revenue
$717,000,000
EBITDA
$-465,000,000
Free Cash Flow
$-221,787,008
Enterprise Value
$2,322,530,816
Total Cash
$292,000,000
Total Debt
$1,202,000,000
Shares Out
98,588,873
Trailing EPS
$-5.83
Book Value
$-2.96
ROE
—
ROA
-24.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 673,000,000 | -535,000,000 | -575,000,000 | 1,532,000,000 | 1,605,000,000 | -80,000,000 | -466,000,000 |
| Dec 2024 | 560,000,000 | -536,000,000 | -569,000,000 | 1,503,000,000 | 1,241,000,000 | 255,000,000 | -414,000,000 |
| Dec 2023 | 434,000,000 | -569,000,000 | -607,000,000 | 1,491,013,000 | 1,215,599,000 | 275,414,000 | -475,000,000 |
| Dec 2022 | 363,329,000 | -648,919,000 | -707,421,000 | 1,545,444,000 | 1,192,950,000 | 352,494,000 | -380,465,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.20
Max Pain — expiry 2026-10-16
max pain strike: $15.00 · spot: $14.41 · call oi: 26,780 · put oi: 16,891Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| OMER | OMEROS CORP | $1.45B | $20.08 | — |
| KLRA | Kailera Therapeutics, Inc. | $1.45B | $11.22 | — |
| AVBP | ArriVent BioPharma, Inc. | $1.40B | $28.45 | — |
| AAPG | ASCENTAGE PHARMA GROUP INTERNATIONAL | $1.39B | $14.86 | — |
| ORIC | Oric Pharmaceuticals, Inc. | $1.36B | $13.16 | — |
News headlines (Yahoo Finance, 1h cache)
RARE Stock Climbs This Week As Investors Look Past Trial Failure To Gene Therapy Launches, Trial Results
2026-09-22 19:09 · Yahoo
FDA Approves Fayuvi. What Does It Mean for Ultragenyx (RARE)’s 2027 Profitability Target?
2026-09-22 10:18 · Yahoo
How Investors Are Reacting To Ultragenyx Pharmaceutical (RARE) First-In-Disease Gene Therapy Approval For FAYUVI
2026-09-19 14:10 · Yahoo
/C O R R E C T I O N -- Andelyn Biosciences/
2026-09-18 13:00 · Yahoo
Ultragenyx Gets A ‘Much-Needed Win,’ Says Cantor – Sees $400M Opportunity After FDA Approves Neurodegenerative Disease Therapy
2026-09-18 12:16 · Yahoo
Abeona Therapeutics® Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI™ Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA)
2026-09-18 11:30 · Yahoo
Ultragenyx (RARE) Surges 12.6%: Is This an Indication of Further Gains?
2026-09-18 11:28 · Yahoo
Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drug
2026-09-18 10:24 · Yahoo
ABEO Stock Gains On Approval For A Drug Abeona Sold, Rating For The One It Sells
2026-09-17 23:33 · Yahoo
Ultragenyx Stock Jumps on Landmark FDA Approval
2026-09-17 21:13 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.